Resverlogix Corp. heads into its May 12 results with the stock at CAD $0.10 — down roughly 5% on the week and 9% over the past month — while short positioning has collapsed to a fraction of where it stood just six weeks ago.
The defining story in the data is the dramatic unwinding of short interest since late March. Short sellers held shares equivalent to roughly 0.032% of the free float in the third week of March — a local peak. By mid-April those positions had been cut to around 0.0025%, before ticking back up this week to 0.0074% of the float. In absolute terms, the estimates are tiny: around 16,400 shares short against a free float of hundreds of millions. The week-on-week percentage jump of ~196% looks alarming in isolation, but the arithmetic is misleading — the base was near zero. Short interest is not a meaningful driver of this stock's story right now.
The lending market reinforces that picture. Borrow availability is extremely loose. Borrowing costs have eased to 0.58% annually, down roughly 64% from their peak above 1% a month ago, and down sharply from the multi-percent levels seen last autumn. Availability of shares to borrow is near its 12-month highs, and the ORTEX short score has drifted to a low 25.8 — ranking in only the 4th percentile of the broader universe, meaning this is far from a crowded short. The borrow market is quiet, frictionless, and largely uninteresting as a signal.
Ownership concentration is the more notable structural feature. Shenzhen Hepalink Pharmaceutical Group holds 26.9% of shares outstanding, a cornerstone stake that has not moved since the last reported date. The next-largest disclosed holders are individuals, with the CFO Aaron Cann the most active name in the insider register. His recent activity tells a routine compensation story: share awards through early 2026, offset by small sell transactions totalling roughly CAD $10,700 in proceeds at prices between $0.04 and $0.105. The net share count over the past 90 days is nominally positive at 100,000 shares, but those are award grants rather than open-market purchases. There is no insider buying signal here in the traditional sense.
Valuation data for RVX is stale — the most recent multiples in the dataset date to 2018 and are not usable as current reference points. No analyst coverage is present in the snapshot, reflecting the reality of a micro-cap biotech trading at a dime on the TSX. The ORTEX sector score sits at the 50th percentile, and the DTC rank is at the 77th percentile, though days-to-cover figures for a name with such minimal short interest carry little practical weight.
What to watch is straightforward: the May 12 earnings release. The most recent event reaction data shows a 4.8% one-day gain on April 15, which itself followed a session of flat performance. The March 13 release produced a 4% decline on the day and a 12% drop over the following week. With the stock at CAD $0.10 and no meaningful short positioning or options data to frame expectations, the May print is essentially a binary clinical or financial update event — the data provides no structural lean either way.
See the live data behind this article on ORTEX.
Open RVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
